2086772-26-9
2086772-26-9
Chemical Structure
Onametostat
Synonym(s): JNJ-64619178
- CAS No.: 2086772-26-9
- Formula:C22H23BrN6O2
- Molecular Weight:483.36
IUPAC Name: (1S,2R,3S,5R)-3-(2-(2-amino-3-bromoquinolin-7-yl)ethyl)-5-(4-amino-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol
InChIKey: DBSMLQTUDJVICQ-CJODITQLSA-N
SMILES: BrC1=C(N)N=C(C=C(CC[C@@H]2[C@@H](O)[C@@H](O)[C@H](N3C(N=CN=C4N)=C4C=C3)C2)C=C5)C5=C1
Biological Activity: Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Onametostat | 99.40% | Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Onametostat (Standard) | ≥98% | Onametostat (Standard) is the analytical standard of Onametostat (HY-101564). This product is intended for research and analytical applications. Onametostat (JNJ-64619178) is a selective, orally active and pseudo-irreversible protein arginine methyltransferase 5 (PRMT5) inhibitor with an IC50 of 0.14 nM. Onametostat has potent activity in lung cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
Structural Analogs
-
Similarity Score 0.85
HY-181294PRMT5-IN-55 -
Similarity Score 0.60
HY-178028PRMT5-IN-53 -
Similarity Score 0.56
HY-142211PRMT5-IN-15 -
Similarity Score 0.52
HY-148469METTL3-IN-3 -
Similarity Score 0.51
HY-163174II399 -
Similarity Score 0.51
HY-141875PRMT5-IN-13 -
Similarity Score 0.51
HY-160865PRMT5-IN-35 -
Similarity Score 0.51
HY-112165PRMT5-IN-2 -
Similarity Score 0.50
HY-107777LLY-283 -
Explore the MedChemAI to find more analogs
References
- [1]. Tongfei Wu, et al. Abstract 4859: JNJ-64619178, a selective and pseudo-irreversible PRMT5 inhibitor with potent in vitro and in vivo activity, demonstrated in several lung cancer models.
- [2]. Tao H, et al. Discovery of Novel PRMT5 Inhibitors by Virtual Screening and Biological Evaluations. Chem Pharm Bull (Tokyo). 2019;67(4):382-388. [Content Brief]
